Yongrong Zhang

发表

Pathogenic effects of glucosyltransferase from Clostridium difficile toxins.

H. Feng, Yongrong Zhang, 2016, Pathogens and disease.

Critical Roles of Clostridium difficile Toxin B Enzymatic Activities in Pathogenesis

N. Oezguen, T. Savidge, Lianfa Shi, 2014, Infection and Immunity.

Mechanisms of Protection against Clostridium difficile Infection by the Monoclonal Antitoxin Antibodies Actoxumab and Bezlotoxumab

A. Therien, H. Feng, H. Yfantis, 2014, Infection and Immunity.

Structure of the full-length Clostridium difficile toxin B

Lan Huang, T. Matsui, H. Feng, 2019, Nature Structural & Molecular Biology.

The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota

H. Feng, Yongrong Zhang, Ashley Saint Fleur, 2022, Gut microbes.

Immunotherapy using IL-2 and GM-CSF is a potential treatment for multidrug-resistant Mycobacterium tuberculosis

Jian Liu, Y. Wang, Yongrong Zhang, 2012, Science China Life Sciences.

A Chimeric Toxin Vaccine Protects against Primary and Recurrent Clostridium difficile Infection

S. Tzipori, T. Savidge, Lianfa Shi, 2012, Infection and Immunity.

Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models.

S. Tzipori, H. Feng, Xingmin Sun, 2012, The Journal of infectious diseases.

The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model.

H. Feng, H. Yfantis, M. Lipsky, 2017, Anaerobe.

Glucosyltransferase activity of Clostridium difficile Toxin B is essential for disease pathogenesis

H. Feng, Zhiyong Yang, Yongrong Zhang, 2015, Gut microbes.

A Segment of 97 Amino Acids within the Translocation Domain of Clostridium difficile Toxin B Is Essential for Toxicity

T. Savidge, Lianfa Shi, H. Feng, 2013, PloS one.

A probiotic yeast-based immunotherapy against Clostridioides difficile infection

H. Feng, J. Galen, T. Hamza, 2020, Science Translational Medicine.

Newly identified bacteriolytic enzymes that target a wide range of clinical isolates of Clostridium difficile

Krunal K. Mehta, R. Kane, J. Dordick, 2016, Biotechnology and bioengineering.

Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.

Lianfa Shi, H. Feng, Kevin Chen, 2016, Pathogens and disease.

, Infection Primary and Recurrent Clostridium difficile A Chimeric Toxin Vaccine Protects against

S. Tzipori, T. Savidge, Lianfa Shi, 2012 .

Mouse Relapse Model of Clostridium difficile Infection

H. Feng, Xingmin Sun, Kevin Chen, 2011, Infection and Immunity.

Mouse Relapse Model of Clostridium difﬁcile Infection (cid:1)

H. Feng, Xingmin Sun, Kevin Chen, 2011 .

Cysteine Protease-Mediated Autocleavage of Clostridium difficile Toxins Regulates Their Proinflammatory Activity

Lianfa Shi, H. Feng, Zhiyong Yang, 2018, Cellular and molecular gastroenterology and hepatology.

Masking autoprocessing of Clostridium difficile toxin A by the C-terminus combined repetitive oligo peptides.

H. Feng, T. Hamza, Yongrong Zhang, 2015, Biochemical and biophysical research communications.

Deletion of sphingosine kinase 2 attenuates cigarette smoke-mediated chronic obstructive pulmonary disease-like symptoms by reducing lung inflammation

Yongrong Zhang, Yanhui Chen, Cheng Rao, 2022, Bosnian journal of basic medical sciences.

Retargeting Clostridium difficile Toxin B to Neuronal Cells as a Potential Vehicle for Cytosolic Delivery of Therapeutic Biomolecules to Treat Botulism

H. Feng, G. Oyler, C. Shoemaker, 2011, Journal of toxicology.

Establishment of a gnotobiotic pig model of Clostridioides difficile infection and disease

H. Feng, Yongrong Zhang, V. Parreno, 2022, Gut Pathogens.

Mice with Inflammatory Bowel Disease are Susceptible to Clostridium difficile Infection With Severe Disease Outcomes.

H. Feng, T. Hamza, Kevin Chen, 2018, Inflammatory bowel diseases.

Delivery of a therapeutic antibody to the lower gastrointestinal tract for the treatment of Clostridium difficile infection (CDI)

S. Hoag, H. Feng, T. Hamza, 2023, Pharmaceutical development and technology.

Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B

J. Jakana, Zhilei Chen, H. Feng, 2019, PLoS biology.

A Multiparticulate Delivery System for Potential Colonic Targeting Using Bovine Serum Albumin as a Model Protein

S. Hoag, H. Feng, Hua Yu, 2017, Pharmaceutical Research.

Structure of the full-length Clostridium difficile toxin B

Lan Huang, T. Matsui, H. Feng, 2019, Nature Structural & Molecular Biology.

Structure of the pore forming fragment of Clostridium difficile toxin B in complex with VHH 5D

T. Matsui, H. Feng, K. Lam, 2019 .

Medical Applications of Clostridia and Clostridial Toxins

G. Oyler, F. Lebeda, T. Kuboki, 2012, Journal of toxicology.

Immunotherapy using IL-2 and GM-CSF is a potential treatment for multidrug-resistant Mycobacterium tuberculosis

Jian Liu, Yongrong Zhang, L. Shao, 2012, Science China Life Sciences.

Correction: Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B

J. Jakana, Junjie Zhang, Zhilei Chen, 2019, PLoS biology.

Critical Roles of Clostridium difficile Toxin B Enzymatic Activities in Pathogenesis

N. Oezguen, T. Savidge, Lianfa Shi, 2014, Infection and Immunity.

A fine-tuned yeast surface-display/secretion platform enables the rapid discovery of neutralizing antibodies against Clostridioides difficile toxins

Zhiyong Yang, Yongrong Zhang, Ashley Saint Fleur, 2023, Microbial Cell Factories.